MedTrace Logo

Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia

NCT06051383 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-01-29

No results posted yet for this study

Summary

Aim of this study is to evaluate the effect of conducting self-management interventions on severity of lower urinary tract symptoms (LUTS) for patients with benign prostatic hyperplasia (BPH).

Research hypothesis:

To fulfill the aim of this study, the following research hypothesis was formulated:

Patients with benign prostatic hyperplasia will suffer less lower urinary tract symptoms (LUTS) after conducting self-management intervention than before conducting.

Conditions

  • Benign Prostatic Hyperplasia

Interventions

OTHER

Self management

patients will be assessed at base line using tool I,II Patients will receive self-management intervention in the form of sessions. Four to six patients in each session. Each session will last approximately 20 minutes Session 1 : * Introduction to the concept of self-management. * Education/reassurance * Managing fluid intake. * Caffeine abstinence * Alcohol advice Session 2 : * Adjusting medications * Constipation advice. * Strategies for dribbling. pelvic floor exercise. * Double-voiding. * Bladder re-training. Session 3: • Booster session All sessions are supported with a self-management booklet given in session. All patients will be reassessed after three months

Sponsors & Collaborators

  • Amna A. Desouky, MD

    lead OTHER

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-06-01
Primary Completion
2024-03-01
Completion
2024-07-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06051383 on ClinicalTrials.gov